Share your videos with the world

Corindus Vascular Robotics, a leading developer of precision vascular robotics, today announced FDA 510(k) clearance has been granted for the CorPath 200 System to be used in percutaneous coronary interventions (PCI). The technology is now approved in the United States to assist interventional cardiologists in performing PCI, a procedure to restore blood flow to blocked arteries in patients with coronary artery disease (CAD). “We are pleased to have received clearance from the FDA for the world’s first system designed for robotic-assisted PCI procedures,” said David M. Handler, President and CEO of Corindus Vascular Robotics. “This is an important milestone for interventional cardiology as we take the next step in transforming the way these procedures are performed in the future. The CorPath System offers hospitals the opportunity to bring robotic-assisted technology benefits to their coronary patients and their physicians.” To view Multimedia News Release, go to http://www.multivu.com/mnr/57343-corindus-vascular-robotics-wins-fda-510k-clearance-for-corpath-200-system

When searching the pharmacy shelves, people looking for help to support healthy good cholesterol with a dietary supplement niacin may inaccurately associate the ingredient nicotinic acid with smoking cessation because it sounds like nicotine, warns leading cardiologist, Dr. Carl Lavie, Medical Director of Cardiac Rehabilitation and Prevention at the John Ochsner Heart and Vascular Institute, New Orleans, LA. In fact, nicotinic acid is the only form of dietary supplement niacin that is clinically proven to support good cholesterol, also known as high-density lipoprotein cholesterol, or HDL. To view Multimedia News Release, go to http://www.multivu.com/mnr/58806-upsher-smith-cardiologist-advice-niacin-nicotinic-acid-flush-free